Synflutide HFA MDI is a combinational product with inhaled corticosteroid fluticasone and long acting beta-2 agonist salmeterol (ICS+LABA). An on-going pivotal bioequivalence PK/Clinical study is conducted and also preparing the international submission dossier. Synflutide HFA MDI have a low ethanol formulation by by using iLEF platform. The indications are asthma and chronic pulmonary obstructive disease (COPD).